Harsh Shah

683 total citations
47 papers, 231 citations indexed

About

Harsh Shah is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Harsh Shah has authored 47 papers receiving a total of 231 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Pathology and Forensic Medicine, 17 papers in Oncology and 14 papers in Genetics. Recurrent topics in Harsh Shah's work include Lymphoma Diagnosis and Treatment (21 papers), Chronic Lymphocytic Leukemia Research (14 papers) and Viral-associated cancers and disorders (6 papers). Harsh Shah is often cited by papers focused on Lymphoma Diagnosis and Treatment (21 papers), Chronic Lymphocytic Leukemia Research (14 papers) and Viral-associated cancers and disorders (6 papers). Harsh Shah collaborates with scholars based in United States, India and Australia. Harsh Shah's co-authors include Luis R. Martinez, Deborah M. Stephens, Ulka N. Vaishampayan, Boyu Hu, Randa Tao, Seongho Kim, Jayme Augusto Bertelli, Lindsey Fitzgerald, David K. Gaffney and Amy J. Davidoff and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Harsh Shah

43 papers receiving 227 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Harsh Shah United States 8 60 59 36 34 31 47 231
Yi‐Bin Chen United States 9 172 2.9× 126 2.1× 45 1.3× 13 0.4× 34 1.1× 12 308
Marcia Wilson United States 8 60 1.0× 54 0.9× 21 0.6× 13 0.4× 62 2.0× 11 316
Andrew J. Wilson United Kingdom 11 40 0.7× 29 0.5× 15 0.4× 12 0.4× 129 4.2× 30 455
Marc Wygoda Israel 7 151 2.5× 22 0.4× 29 0.8× 30 0.9× 118 3.8× 35 390
Shanna Gustafson United States 12 79 1.3× 109 1.8× 84 2.3× 7 0.2× 95 3.1× 16 636
Iqbal Qasim India 11 74 1.2× 43 0.7× 78 2.2× 16 0.5× 125 4.0× 31 351
Nathalie J. Hijmering Netherlands 9 108 1.8× 168 2.8× 34 0.9× 18 0.5× 20 0.6× 16 425
Luis Antonio Lucio López Mexico 6 94 1.6× 171 2.9× 109 3.0× 27 0.8× 9 0.3× 13 274
Julian Barwell United Kingdom 14 121 2.0× 66 1.1× 43 1.2× 8 0.2× 174 5.6× 33 749

Countries citing papers authored by Harsh Shah

Since Specialization
Citations

This map shows the geographic impact of Harsh Shah's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Harsh Shah with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Harsh Shah more than expected).

Fields of papers citing papers by Harsh Shah

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Harsh Shah. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Harsh Shah. The network helps show where Harsh Shah may publish in the future.

Co-authorship network of co-authors of Harsh Shah

This figure shows the co-authorship network connecting the top 25 collaborators of Harsh Shah. A scholar is included among the top collaborators of Harsh Shah based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Harsh Shah. Harsh Shah is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Roberts, Alison, Raquel Aguiar‐Ibáñez, Harsh Shah, et al.. (2024). PCR262 Understanding the Experience of Patients With Early-Stage Cancers: A Targeted Qualitative Literature Review. Value in Health. 27(12). S558–S558. 1 indexed citations
2.
Bock, Allison M., Joshua J. Horns, Harsh Shah, et al.. (2024). Real-World Comparison of BCL2 Inhibitor and BTK Inhibitor Therapy in the Front-Line Treatment of CLL Including Patients with Del(17p)/TP53 Mutation. Blood. 144(Supplement 1). 1864–1864.
3.
Stuver, Robert, Esther Drill, Nivetha Ganesan, et al.. (2023). Outcomes for Patients with Classical Hodgkin Lymphoma Who Relapse after Autologous Stem Cell Transplant in the Era of Novel Therapies. Blood. 142(Supplement 1). 3069–3069. 1 indexed citations
4.
Khopade, Ajay J., et al.. (2023). Low dose ophthalmic solution of difluprednate for the management of pain and inflammation. Journal of Drug Delivery Science and Technology. 83. 104387–104387. 7 indexed citations
5.
Shah, Harsh, Lindsey Fitzgerald, Randa Tao, et al.. (2023). Survival Outcomes of Limited-Stage Diffuse Large B-Cell Lymphoma Treated With Radiation Therapy. Clinical Lymphoma Myeloma & Leukemia. 24(2). 94–104.e6. 1 indexed citations
6.
Khopade, Ajay J., et al.. (2023). A Comparative Preclinical Evaluation of a Novel Difluprednate 0.04% BID Ophthalmic Solution and Marketed 0.05% QID Ophthalmic Emulsion. Journal of Ocular Pharmacology and Therapeutics. 40(1). 57–66. 1 indexed citations
7.
Goyal, Gaurav, Amy J. Davidoff, Scott F. Huntington, et al.. (2023). The COVID-19 Pandemic and In-Person Visit Rate Disruptions Among Patients With Hematologic Neoplasms in the US in 2020 to 2021. JAMA Network Open. 6(6). e2316642–e2316642. 5 indexed citations
8.
Shah, Harsh & Jayme Augusto Bertelli. (2023). Long-Term Donor-Site Morbidity Following Entire Sural Nerve Harvest for Grafting. The Journal Of Hand Surgery. 48(11). 1173.e1–1173.e7. 3 indexed citations
9.
Stephens, Deborah M., Kenneth M. Boucher, David A. Wada, et al.. (2023). YIA23-004: Non-Melanoma Skin Cancer (NMSC) in Patients With Chronic Lymphocytic Leukemia (CLL): Biology and Prevention. Journal of the National Comprehensive Cancer Network. 21(3.5). YIA23–4.
10.
Stephens, Deborah M., Ying Huang, Amy S. Ruppert, et al.. (2022). Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study. Clinical Cancer Research. 28(15). 3242–3247. 20 indexed citations
11.
Wagner, Charlotte B, Kenneth M. Boucher, Ivana N. Micallef, et al.. (2022). Real-world outcomes of brentuximab vedotin maintenance after autologous stem cell transplant in relapsed/refractory classical Hodgkin lymphoma: Is less enough?. Journal of Clinical Oncology. 40(16_suppl). 7514–7514. 2 indexed citations
12.
Chipman, Jonathan, Matthew Parsons, Randa Tao, et al.. (2022). Second Primary Malignancies in Diffuse Large B-cell Lymphoma Survivors with 40 Years of Follow Up: Influence of Chemotherapy and Radiation Therapy. Advances in Radiation Oncology. 7(6). 101035–101035. 4 indexed citations
13.
Shah, Harsh, et al.. (2022). Influence of racial and ethnic identity on overall survival in patients with chronic lymphocytic lymphoma.. Journal of Clinical Oncology. 40(16_suppl). 7508–7508. 2 indexed citations
14.
Shah, Harsh, et al.. (2022). Survival outcomes in patients with chronic lymphocytic leukemia treated at academic centers.. Journal of Clinical Oncology. 40(16_suppl). 7544–7544. 2 indexed citations
15.
Johnson, Eric D., et al.. (2021). Bortezomib for the Management of Relapsed or Refractory Warm Autoimmune Hemolytic Anemia: A Scoping Review. Blood. 138(Supplement 1). 4149–4149. 3 indexed citations
16.
Shah, Harsh, et al.. (2021). Treatment Outcomes of Consolidative Radiation in Extranodal Early-Stage Diffuse Large B-Cell Lymphoma. Blood. 138(Supplement 1). 49–49. 1 indexed citations
17.
Vaishampayan, Ulka N., Harsh Shah, Dongping Shi, et al.. (2020). Adrenal Metastases as Sanctuary Sites in Advanced Renal Cancer. PubMed. 7(4). 1–7. 5 indexed citations
18.
Shah, Harsh & Ulka N. Vaishampayan. (2018). Therapy of Advanced Prostate Cancer: Targeting the Androgen Receptor Axis in Earlier Lines of Treatment. Targeted Oncology. 13(6). 679–689. 13 indexed citations
19.
Shah, Harsh, et al.. (2016). Neuroendocrine Differentiation of a Primary BRAF Mutant Colon Cancer in a Patient With a History of Hairy Cell Leukemia. Clinical Colorectal Cancer. 15(4). e235–e239. 1 indexed citations
20.
Shah, Harsh, et al.. (2014). Steroid Unresponsive Case of Ulcerative Mucha-Habermann Disease (Febrile Ulcernecrotic Mucha-Habermann Disease) Treated with Methotrexate. Indian Journal of Dermatology. 59(6). 631–631. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yi‐Bin Chen Breakdown of academic impact, for papers by Marcia Wilson Breakdown of academic impact, for papers by Andrew J. Wilson Breakdown of academic impact, for papers by Marc Wygoda Breakdown of academic impact, for papers by Shanna Gustafson Breakdown of academic impact, for papers by Iqbal Qasim Breakdown of academic impact, for papers by Nathalie J. Hijmering Breakdown of academic impact, for papers by Luis Antonio Lucio López Breakdown of academic impact, for papers by Julian Barwell
Rankless by CCL
2026